重新配制的万珂应当在制备后8个小时内使用。
Reconstituted VELCADE should be administered within 8 hours of preparation.
您认为含万珂的化疗方案与传统方案相比,有什么优势?
Compared to traditional chemotherapy, what is the advantage of Velcade?
波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。
Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.
波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。
Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.
应用推荐